Brachytherapy Approach Using \(^{177}\)Lu Conjugated Gold Nanostars and Evaluation of Biodistribution, Tumor Retention, Dosimetry and Therapeutic Efficacy in Head and Neck Tumor Model

Min-Ying Lin \(^1,1\), Hsin-Hua Hsieh \(^1,3\), Jyh-Cheng Chen \(^1,3\), Chuan-Lin Chen \(^1\), Nin-Chu Sheu \(^3\), Wen-Sheng Huang \(^2\), Shinn-Ying Ho \(^3\), Ting-Wen Chen \(^3,4\), Yi-Jang Lee \(^1,5\) and Chun-Yi Wu \(^1,+,\)

1. Introduction

Head and neck squamous cell carcinoma (HNSCC) ranks sixth in incidence around the world. The 5-year survival rate of HNSCC is around 65% and locoregional recurrence is believed to be a major limitation of various treatments, including surgical and nonsurgical strategies \[^{1,2}\]. Unlike other cancers that occur in parenchymal organs, the dissemination of HNSCC is mainly caused by local invasion instead of distant metastasis \[^{3}\]. Local invasion of HNSCC is also a risk factor of recurrence after therapy, and the mechanism of
local invasion has been reported to be associated with epithelial-mesenchymal transition (EMT) of tumor cells [4,5]. A recent report demonstrated that EMT can be regarded as a prognostic factor for HNSCC patients who undergo chemoradiotherapy [6]. Rhenium-188 composed of radiopharmaceuticals with diagnostic and therapeutic capacity also exhibit significant effects on repressing EMT markers of orthotopic HNSCC tumor model [7]. Radiopharmaceuticals or radionuclides are considered as neoadjuvant high-dose-rate brachytherapy for breast cancer or cervical cancer [8,9]. For recurrent HNSCC, high-dose-rate brachytherapy has also been reported to improve overall survival without unacceptable acute toxicity [10,11]. Therefore, the development of specific radiopharmaceuticals is needed for local treatment of advanced HNSCC and to reduce potential side effects raised by radioactivity.

Certain radionuclides emit both moderate- or high-energy particles and low-energy γ-rays that can be used for in vivo diagnosis and therapy concomitantly, the so-called theranostics. Lutetium-177 (∿Lu) is probably the most attractive theranostic radionuclide contemporarily as it shows therapeutic advantages in various fields of preclinical and clinical communities [12–14]. ∿Lu exists in an oxidative state of +3 charge that allows it to be easily radiolabeled to a variety of molecular carriers, and this property is important for the design of targeted radionuclide therapy (TRT) [15]. ∿Lu emitted 78% of 0.497 MeV β− particles (Eβ(max)) and 11% of 0.208 MeV γ-rays that can be used for theranostics and dosimetry [16]. The therapeutic efficacy of moderate-energy β− particles can be compensated by a relatively long half-life (6.65 days) and high activity of ∿Lu during the preparation of radiopharmaceuticals and administration to patients. The mean emission range of β− particles delivered by ∿Lu is 670 µm [15]. The diameter of one mammalian cell is around 100 µm, therefore, ∿Lu is ideal for the treatment of local invaded tumor cells and surface tumors with low damage to nearby normal tissues. Therefore, the physical and chemical characteristics of ∿Lu seem applicable for its administration in local advanced HNSCC. However, little is known if ∿Lu formed radiopharmaceuticals can be used for local theranostics of HNSCC, at least in a preclinical model.

Gold nanostars (AuNS) belong to a specific shape of gold nanoparticles (GNP) that constitute a solid metal core decorated with multiple sharp branches [17]. AuNS have been used as a substrate for surface-enhanced Raman scattering (SERS), localized surface plasmon resonance (LSPR) sensing, and refractive index (RI) sensing [18–20]. Studies have also demonstrated that AuNS are biocompatible and their biomedical applications, including diagnosis, bioimaging, photothermal therapy, and target drug delivery are of interest [21–24]. For instance, AuNS can be used as photothermal agents for cancer treatment because of the high conversion efficiency raised by the near-infrared (NIR) laser [25,26]. A similar approach using NIR light irradiation can also stimulate the release of a chemotherapeutic agent coated on AuNS [27]. However, whether AuNS can be used as a nanocarrier for radionuclides and applied in tumor imaging and therapy remains to be addressed. ∿Lu-labeled GNP is found to be highly effective for inhibiting the growth of breast cancer in tumor-bearing mice by intratumoral administration [28], the radiolabeling of AuNS is also speculated to be also applicable to theranostics in the HNSCC tumor model.

Based on the promising theranostic properties of ∿Lu and the nature of the gold nanostars, we aim to develop PEGylated coated AuNS for conjugating ∿Lu via a DTPA chelator and determine their biodistribution by using noninvasive imaging as well as the therapeutic efficacy. To the best of our knowledge, this is the first report proposing the preclinical application of ∿Lu labeled AuNS in the human HNSCC tumor model.

2. Materials and Methods

2.1. Preparation and Characterization of ∿Lu-Labeled pAuNS (∿Lu-DTPA-pAuNS)

The manufacturing procedure of gold nanostars (AuNS) has been described previously [26]. Poly(ethylene glycol) methyl ether thiol (45 mg, SH-PEG6000-CH3, Sigma-Aldrich, St. Louis, MO, USA) and Thiol PEG amine (15 mg, SH-PEG2K-NH2, Sigma-Aldrich, St. Louis, MO, USA) were added to the AuNS solution. The mixture was
kept at room temperature for 2 h with gentle shaking. After the reaction, the solution was centrifuged at 12,000 × g for 15 min to remove unconjugated compounds in the supernatant. The pellet was resuspended in ddH₂O. To this solution, the chelate, p-SCN-Bn-DTPA (0.5 mg, Macrocyclics, Plano, TX, USA) dissolved in 0.05 M of sodium bicarbonate buffer (pH = 9.2), was added and the mixture was reacted at 60 °C for 4 h. The unreacted chelate was removed by centrifugation (12,000 × g, 15 min) to give DTPA-pAuNS as a pellet, which was washed with ddH₂O twice for radiolabeling. ¹⁷⁷Lu-LuCl₃ (ITG Isotope Technologies Garching GmbH, Garching, Germany) and DTPA-pAuNS (¹⁷⁷Lu-LuCl₃/DTPA-pAuNS = 10 µCi/1 µg) were added to a vial containing HEPES buffer (0.1 M, pH = 4.5) and the mixture was allowed to react at 30 °C for 30 min. After the reaction, excess DTPA solution (10 mM) was loaded for a 30-min challenge. Finally, the mixture was centrifuged at 10,000 × g for 10 min to obtain the product, ¹⁷⁷Lu-DTPA-AuNS. The labeling efficiency and radiochemical purity were determined by radio-thin layer chromatography (radio TLC) using sodium citrate buffer (0.5 M, pH = 5.0) as mobile phase on an ITLC plate (ITLC-SG, Merck, Darmstadt, Germany).

2.2. Cell Lines

Human tongue squamous cell carcinoma SAS cells were obtained from Prof. Muh-Hwa Yang (National Yang Ming Chiao Tung University, Taipei, Taiwan) and SAS-3R cells (a stable cell line with multiple reporter genes, including green fluorescent protein gene, firefly luciferase gene and herpes simplex virus type 1-thymidine kinase gene) harboring a pLT-3R construct with multiple reporter genes were maintained as described in a previous report [29]. Cells were maintained in DMEM (Life Technologies Inc., Carlsbad, CA, USA). All cell lines were supplemented with 10% fetal bovine serum (Thermo Fisher Scientific Inc., Waltham, MA, USA), 2 mM L-glutamine, and 50 U/mL penicillin. Cells were incubated at 37 °C in a humidified incubator containing 5% CO₂.

2.3. Human HNSCC Tumor-Bearing Animal Model

The SAS-3R cells were implanted on BALB/c nude mice with orthotopic injection. The SAS-3R cells were carefully cultured and resuspended in OPTI-MEM (Sigma-Aldrich, St. Louis, MO, USA) at a concentration of 10⁶ cells/50 µL. The mice were anesthetized and placed supine. The mouth was opened and the 27G needle syringe (Terumo Co., Tokyo, Japan) was then inserted for 5 mm and injected through the outer muscle of the lower jaw on the right side of mice. All the experiment animals were approved by the Institutional Animal Care and Use Committee (IACUC No. 1081009).

2.4. Analysis of Biodistribution of ¹⁷⁷Lu-DTPA and ¹⁷⁷Lu-DTPA-pAuNS

The tumor-bearing mice were randomly assigned to two groups for intratumoral injection of ¹⁷⁷Lu-DTPA and ¹⁷⁷Lu-DTPA-pAuNS followed by biodistribution. Mice were sacrificed by CO₂ asphyxiation to collect organs and tumors after 4, 24, and 72 h of injection. Collected organs were weighed and counted by the γ-scintillation counter (1470 WIZARD Gamma Counter, Wallac, Finland). The results are presented as the percentage injected dose per gram tissue (% ID/g).

2.5. MicroSPECT Imaging of ¹⁷⁷Lu-DTPA-pAuNS in Tumor-Bearing Mice

When the SAS-3R tumor volume reached 100–150 mm³, the mice were randomly categorized into three groups, (a) receiving intravenous (400 μCi/100 µL), (b) intratumoral injection of ¹⁷⁷Lu-DTPA-pAuNS and (c) intratumoral injection of ¹⁷⁷Lu-DTPA (200 μCi/50 µL), respectively. After administration of ¹⁷⁷Lu-DTPA or ¹⁷⁷Lu-DTPA-pAuNS, we performed microSPECT/CT imaging to acquire signals using the small animal PET/SPECT/CT scanner (FLEX Triumph Regular FLEX X-OCT, SPECT CZT 3 Head System, Gamma Medica, Northridge, CA, USA). Each tumor-bearing mouse was laid in the prone position and anesthetized with 1–2% isoflurane (v/v) in 2 L oxygen. The images were reconstructed by using an ordered-subsets expectation-maximization (OSEM) algorithm. For imaging conditions,
since the scanner has still not yet set the imaging protocol of $^{177}$Lu, the protocol of $^{111}$In with similar gamma-ray energy was used for imaging. Each mouse was first positioned by CT scan, then a SPECT scan was performed for 30 min, and the image was reconstructed using OSEM with 20 iterations. We then used Amide’s Medical Image Data Examiner (AMIDE 1.0.4) software to perform semi-automatic region of interest (ROI) drawing and semi-quantitative analysis of the tumor areas in the reconstructed images. After each ROI was circled by AMIDE software, we calculated the cylinder factor obtained from the reference source. The procedure included (a) determining the activity by measuring with a well-type ion chamber, (b) keeping it in a cylindrical container with a fixed volume (cc), (c) scanning the cylinder, reconstructing the image and encircling the ROI and (d) calculating the cylinder factor. The cylinder factor and the injection activity of each mouse were input into AMIDE. Accordingly, we could obtain semi-quantitative data in %ID/cc as the unit.

2.6. Evaluation of Therapeutic Efficacy of $^{177}$Lu-DTPA-pAuNS in Tumor-Bearing Mice

For evaluation of therapeutic efficacy, the tumor viability and growth rate were assessed using the luciferase-based reporter gene imaging (IVIS 50, Perkin Elmer Inc., Waltham, MA, USA) and caliper measurement, respectively. A caliper was used to measure tumor dimensions and its size (mm$^3$) was calculated as $0.5 \times \text{width}^2 \times \text{length}$. For survival analysis, the endpoint of each datum was established since the first mice died from the treatment. The Kaplan-Meier plot was used for demonstration of survival.

2.7. Evaluation of Therapeutic Efficacy of pAuNS-Mediated Optothermal Therapy

The mice in the control and treated group received intratumoral injections of $^{177}$Lu-DTPA and $^{177}$Lu-DTPA-pAuNS (10 mg/kg), respectively. After injection, a 6-min laser (793 nm, 1 W/cm$^2$) exposure was performed. The increase in temperature was monitored by a digital thermometer using a thermocouple. The treatment response was determined by measuring tumor burden and hematoxylin and eosin staining.

2.8. Dosimetric Evaluation of $^{177}$Lu-DTPA-pAuNS Absorbed Radiation Dose In Vivo

For estimating the radiation absorption dose of various tissues/organs in the human body, the mean absorbed dose in various tissues was calculated from the radionuclide concentration in tissues/organs, and the relative tissue/organ weight was calculated based on previous studies. Based on the results of the biodistribution study in mice, the calculated mean value of the percentage of injected activity per gram of tissue/organ (%IA/g) was extrapolated to present the uptake in organs of a 73 kg adult using the following formula:

\[
\left(\frac{\%\text{IA}/\text{organ}_{\text{mice}} \times (\text{kg}_{\text{total body weight}}_{\text{mice}}) \times (\text{g}_{\text{organ}}/\text{Kg}_{\text{total body weight}}_{\text{human}})}{\%\text{IA}/\text{organ}_{\text{human}}}\right)
\]

The extrapolated values (%IA) in the human organs at 4, 24, 48 and 72 h were exponentially fitted and integrated to obtain the number of disintegrations in source organs. The value of each source organ was entered into the OLINDA/EXM 1.0 software for the dosimetry estimation. For tumor absorbed dose, the number of disintegrations was calculated and entered into the sphere modeling of OLINDA/EXM 1.0 software to estimate the absorbed dose of tumor in each spheroid mass.

2.9. Hematoxylin and Eosin (H&E) Staining

Tumor sections were prepared for formalin-fixed paraffin-embedded tissues and selected according to the morphology catalog of the diagnosis. The sections were dewaxed in an oven at 60 °C, and de-paraffinized by xylene, followed by rehydration in an alcohol solution. The tissue sections were stained with hematoxylin and eosin.

2.10. Statistical Analysis

The results obtained in this study were analyzed by Student’s $t$-test, and $p < 0.05$ was determined as a significant difference. All data were represented as mean ± standard
deviation or mean ± standard error of the mean. The Kaplan-Meier method with the
log-rank test was used to compare survival rates among different treatments.

3. Results
3.1. Design of $^{177}$Lu Conjugated pAuNS for the Treatment of HNSCC In Vivo

The theranostic radionuclide $^{177}$Lu was conjugated to the PEGylated AuNS (pAuNS). Figure 1 illustrates the preparation of $^{177}$Lu conjugated pAuNS via DTPA chelator, the evaluation of tumor accumulation, dosimetry, and therapeutic efficacy after intratumoral administration. The radio TLC analysis showed that the labeling efficiency of $^{177}$Lu-DTPA-pAuNS was around 87%, and the EDTA challenge with excess EDTA did not significantly affect the labeling efficiency (Figure 1B). After purification by centrifugation, the radiochemical purity (RCP) was 95 ± 3% (Figure 1C). In addition, the radiochemical yield was 50 ± 5%, determined by the radioactivity of the final product over that of initially added $^{177}$Lu. The TEM visualization demonstrated that the shape and the size of pAuNS were not significantly changed before and after conjugation of $^{177}$Lu (Figure 1D).

Figure 1. Construction and Radiolabeling of $^{177}$Lu labeled PEGylated gold nanostars ($^{177}$Lu-DTPA-pAuNS). (A) Flow chart
of the preparation of $^{177}$Lu-DTPA-pAuNS and the application of theranostic strategy. (B,C) RadioTLC analysis shows the labeling efficiency after Lu-177 labeling, EDTA challenge and centrifugation. (D) Transmission electron microscopy (TEM) images of pAuNS and $^{177}$Lu-DTPA-pAuNS.

### 3.2. Analysis of $^{177}$Lu-DTPA-pAuNS Biodistribution in an Orthotopic HNSCC Tumor Model

The biodistribution of intratumorally injected $^{177}$Lu-DTPA-pAuNS and $^{177}$Lu-DTPA was quantitatively analyzed. The results showed that the level of $^{177}$Lu-DTPA-pAuNS was still high in tumor lesions up to 72 h, whereas a little radioactivity was detected in the liver (Figure 2). Free $^{177}$Lu-DTPA was only detected in tumor lesions for 24 h and also very little in different organs. The tumor-to-muscle (T/M) and tumor-to-blood ratios (T/B) of $^{177}$Lu-DTPA-pAuNS at different time points were also calculated (Table 1). For intravenous injection of $^{177}$Lu-DTPA-AuNS, most of the drug was accumulated in the liver and kidney rather than tumors (Table S1).

![Figure 2](image-url)  
**Figure 2.** Biodistribution analysis of $^{177}$Lu-DTPA (Blue bars) and $^{177}$Lu-DTPA-pAuNS (Red bars) after intratumoral injection in orthotopic HNSCC tumor-bearing mice. Radioactivity distribution in each organ is demonstrated by bar chart (n = 4).

| Organ       | 4 h (n=4) | 24 h (n=4) | 48 h (n=4) | 72 h (n=4) |
|-------------|-----------|------------|------------|------------|
| Blood       | 5.43 ± 3.78 | 0.16 ± 0.03 | 0.21 ± 0.07 | 0.15 ± 0.02 |
| Heart       | 1.14 ± 0.65 | 0.27 ± 0.13 | 0.23 ± 0.05 | 0.17 ± 0.09 |
| Lung        | 2.59 ± 0.95 | 0.81 ± 0.44 | 0.62 ± 0.33 | 0.54 ± 0.27 |
| Liver       | 8.91 ± 4.50 | 17.68 ± 6.47 | 10.43 ± 4.01 | 7.85 ± 5.02 |
| Stomach     | 0.59 ± 0.10 | 0.36 ± 0.07 | 0.39 ± 0.10 | 0.31 ± 0.02 |
| Small int.  | 0.81 ± 0.25 | 0.61 ± 0.29 | 0.74 ± 0.38 | 0.74 ± 0.03 |
| Large int.  | 0.51 ± 0.17 | 0.20 ± 0.06 | 0.25 ± 0.09 | 0.15 ± 0.07 |
| Spleen      | 5.99 ± 1.34 | 8.49 ± 2.74 | 8.85 ± 2.77 | 2.53 ± 2.11 |
| Pancreas    | 0.65 ± 0.25 | 0.12 ± 0.05 | 0.13 ± 0.04 | 0.14 ± 0.03 |
| Kidney      | 8.97 ± 1.79 | 7.04 ± 2.07 | 4.31 ± 0.79 | 4.23 ± 1.56 |
| Bone        | 0.65 ± 0.09 | 0.88 ± 0.06 | 1.74 ± 0.41 | 2.20 ± 0.89 |
| Muscle      | 0.28 ± 0.14 | 0.07 ± 0.10 | 0.10 ± 0.05 | 0.04 ± 0.05 |
| Tumor       | 125.09 ± 27.26 | 120.08 ± 51.32 | 35.62 ± 6.85 | 61.44 ± 14.81 |
| BM          | 2.12 ± 1.35 | 0.55 ± 1.01 | 2.15 ± 0.86 | 0.00 ± 0.00 |
| Brain       | 0.16 ± 0.08 | 0.02 ± 0.03 | 0.02 ± 0.01 | 0.03 ± 0.04 |
| Urine       | 183.23 ± 81.08 | 11.41 ± 10.71 | 2.04 ± 1.10 | 2.49 ± 2.87 |
| T/M         | 377.17 ± 154.53 | 167.36 ± 182.73 | 354.16 ± 152.19 | 1499.10 ± 279.39 |
| T/B         | 23.02 ± 41.25 | 747.62 ± 879.15 | 169.42 ± 71.88 | 416.33 ± 110.57 |

*Table 1.* The biodistribution of $^{177}$Lu-DTPA-pAuNS injected intratumorally into tumor-bearing mice *a*.

---

*a* Unit: percent of injection dose/gram of organ or tissue (%ID/g); *b* BM: Bone marrow; T/M: tumor-to-muscle; T/B tumor-to-blood ratio.
3.3. MicroSPECT/CT for Evaluation of Intratumoral Injection in HNSCC Tumor

We next compared the tumorous accumulation of $^{177}$Lu-DTPA and $^{177}$Lu-DTPA-pAuNS in the orthotopic tumor model. The photon signals of $^{177}$Lu-DTPA-pAuNS injected tumor were significantly higher than that of $^{177}$Lu-DTPA injected tumor detected by μSPECT/CT imaging (Figure 3A). No photon signals were detected in other organs of tumor-bearing mice. The imaging result was also semi-quantified by measuring the mean radioactivity in each ROI (Figure 3B). Positive correlations of SPECT imaging and biodistribution were also observed in the tumor uptakes of $^{177}$Lu-DTPA-pAuNS and $^{177}$Lu-DTPA (Figure 3C,D).

![Figure 3](image_url)

**Figure 3.** The evaluation of microSPECT/CT in HNSCC orthotopic tumor after intratumoral injection. (A) microSPECT/CT imaging of $^{177}$Lu-DTPA and $^{177}$Lu-DTPA-pAuNS accumulations in orthotopic HNSCC tumor-bearing mice. (B) The time activity curve shows the activity of the tumor area circled by the ROI (n = 3). (C,D) The correlation of biodistribution analysis (%ID/g) and semi-quantitative analysis (%ID/cc) in $^{177}$Lu-DTPA-pAuNS and $^{177}$Lu-DTPA.
3.4. Evaluation of Therapeutic Efficacy of $^{177}$Lu-DTPA-pAuNS and $^{177}$Lu-DTPA in Tumor-Bearing Mice

To evaluate the therapeutic efficacy of $^{177}$Lu-DTPA-pAuNS in vivo, SAS cells harboring the luciferase reporter gene were used for the establishment of an orthotopic tumor model followed by bioluminescent imaging. The schedule for tumor implantation, drug injection, and in vivo imaging are illustrated in Figure 4A. $^{177}$Lu-DTPA-pAuNS and $^{177}$Lu-DTPA (7.4 MBq each) were separately injected into the tumor lesions of small animals. The bioluminescent imaging was acquired using the IVIS 50 system. The results showed that $^{177}$Lu-DTPA-pAuNS suppressed the luciferase activity, but $^{177}$Lu-DTPA did not (Figure 4B). The photon flux was quantified to draft the curves for comparison (Figure 4C). The tumor growth curves also demonstrated reduced rates of tumor growth in the $^{177}$Lu-DTPA-pAuNS treated group (Figure 4D).

Figure 4. Monitoring the therapeutic efficacy of $^{177}$Lu-DTPA-pAuNS administrated in HNSCC
tumor-bearing mice. (A) The experimental scheme for $^{177}$Lu-DTPA-pAuNS treatment. (B) The bioluminescence imaging of tumor growth responding to $^{177}$Lu-DTPA-pAuNS and untreated control. (C) Quantification of the bioluminescence intensity change; *: $p < 0.05$ (D) The tumor volume of mice in each group. The mice in the control group, $^{177}$Lu-DTPA-injected group, and $^{177}$Lu-DTPA-pAuNSs-injected group were treated with normal saline, 200 µCi of $^{177}$Lu-DTPA and 200 µCi of $^{177}$Lu-DTPA-pAuNSs, respectively (n = 5); *: $p < 0.05$; ns: non-significant.

3.5. Increase of Survival Rate of HNSCC Tumor-Bearing Mice by $^{177}$Lu-DTPA-pAuNS

The body weights of mice did not decrease more than 80% after treatment of $^{177}$Lu-DTPA-AuNS or $^{177}$Lu-DTPA up to 20 days (Figure 5A). Intratumoral injection of $^{177}$Lu-DTPA-pAuNS showed a higher survival rate in tumor-bearing mice than $^{177}$Lu-DTPA (Figure 5B). Therefore, $^{177}$Lu-DTPA-pAuNS has the potential of good therapeutic efficacy by long-term tumor retention and low toxicity using the brachytherapy approach.

Figure 5. (A) The body weight of the mice in each group during the treatment course. The mice in the control group, $^{177}$Lu-DTPA-injected group, and $^{177}$Lu-DTPA-pAuNSs-injected group were treated with normal saline, 200 µCi of $^{177}$Lu-DTPA, and 200 µCi of $^{177}$Lu-DTPA-pAuNSs, respectively (n = 5). (B) The percentage of survival for each group at indicated time points.

3.6. Estimation of Dosimetry in Human Organs by the Treatment of $^{177}$Lu-DTPA-pAuNS

The OLINDA/EXM method was used to estimate the absorbed radiation dose in systemic organs and tumor lesion of a 73 kg adult according to the biodistribution data in HNSCC tumor-bearing mice with intratumoral injection of $^{177}$Lu-DTPA-pAuNS. The results showed the highest absorbed dose in the liver (0.329 mSv/MBq), kidney (0.135 mSv/MBq), and spleen (0.138 mSv/MBq) (Table 2). The sphere model was used to estimate the absorbed dose of the tumor at 0.5 g (3.55 mGy/MBq), and it is significantly higher than that absorbed by all organs. The ratios of absorbed doses for tumor-to-brain and tumor-to-thyroid were 1517.1 and 2909.8, respectively. The estimated absorbed radiation dose in tumor-bearing mice intravenously injected with $^{177}$Lu-DTPA-pAuNS (Table 3) was 1.97, 0.16 and 1.37 mSv/MBq, respectively, in the liver, kidney, and spleen. However, the absorbed dose of 0.5 g tumorsphere was only 0.038 mGy/MBq. The ratios of absorbed doses for tumor-to-brain and tumor-to-thyroid were 9.9 and 0.54, respectively. Therefore, the intratumoral injection of $^{177}$Lu-DTPA-pAuNS was found to be more efficient in the delivery of radiation dose to the tumor but led to less radiation damage to vital organs compared to that by intravenous injection of $^{177}$Lu-DTPA-pAuNS.
Table 2. Radiation dose estimates for intratumoral injection of $^{177}$Lu-DTPA-pAuNS in an adult human $^a$.

| Target Organ $^b$          | Absorbed Dose (mSv/MBq) |
|----------------------------|--------------------------|
| Adrenals                   | $4.92 \times 10^{-3}$    |
| Brain                      | $2.34 \times 10^{-3}$    |
| Breasts                    | $1.50 \times 10^{-3}$    |
| Gallbladder Wall           | $7.43 \times 10^{-3}$    |
| LLI Wall                   | $5.06 \times 10^{-3}$    |
| Small Intestine            | $5.62 \times 10^{-3}$    |
| Stomach Wall               | $7.17 \times 10^{-3}$    |
| ULI Wall                   | $2.52 \times 10^{-3}$    |
| Heart Wall                 | $2.22 \times 10^{-2}$    |
| Kidneys                    | $1.35 \times 10^{-1}$    |
| Liver                      | $3.29 \times 10^{-1}$    |
| Lungs                      | $2.61 \times 10^{-2}$    |
| Muscle                     | $3.53 \times 10^{-3}$    |
| Ovaries                    | $1.48 \times 10^{-3}$    |
| Pancreas                   | $2.13 \times 10^{-3}$    |
| Red Marrow                 | $1.25 \times 10^{-3}$    |
| Skin                       | $1.37 \times 10^{-3}$    |
| Spleen                     | $9.93 \times 10^{-4}$    |
| Thymus                     | $1.64 \times 10^{-3}$    |
| Thyroid                    | $1.22 \times 10^{-3}$    |
| Urinary Bladder Wall       | $1.14 \times 10^{-3}$    |
| Uterus                     | $1.38 \times 10^{-3}$    |
| Tumor (0.5 g) $^c$         | $3.55 \times 10^{0}$     |
| Total Body                 | $1.69 \times 10^{-2}$    |
| Effective Dose             | $2.51 \times 10^{-2}$    |

$^a$ The radiation dosimetry was converted from the biodistribution of $^{177}$Lu-pAuNS in 0.025 kg mice to 73 kg male adults. $^b$ LLI: Lower Large Intestine; ULI: Upper Large Intestine. $^c$ The tumor absorbed dose was obtained by the sphere model. The unit is mGy/MBq because no organ weighting factor is available for the sphere model.

Table 3. Radiation dose estimates for intravenous injection of $^{177}$Lu-DTPA-pAuNS in an adult human $^a$.

| Target Organ $^b$          | Absorbed Dose (mSv/MBq) |
|----------------------------|--------------------------|
| Adrenals                   | $9.06 \times 10^{-2}$    |
| Brain                      | $3.86 \times 10^{-3}$    |
| Breasts                    | $7.09 \times 10^{-2}$    |
| Gallbladder Wall           | $1.08 \times 10^{-1}$    |
| LLI Wall                   | $7.77 \times 10^{-2}$    |
| Small Intestine            | $8.76 \times 10^{-2}$    |
| Stomach Wall               | $8.14 \times 10^{-2}$    |
| ULI Wall                   | $8.02 \times 10^{-2}$    |
| Heart Wall                 | $2.14 \times 10^{-2}$    |
| Kidneys                    | $1.60 \times 10^{-1}$    |
| Liver                      | $1.97 \times 10^{0}$     |
| Lungs                      | $6.37 \times 10^{-2}$    |
| Muscle                     | $1.14 \times 10^{-2}$    |
| Ovaries                    | $7.40 \times 10^{-2}$    |
| Pancreas                   | $5.01 \times 10^{-2}$    |
| Red Marrow                 | $5.71 \times 10^{-2}$    |
| Skin                       | $6.83 \times 10^{-2}$    |
| Spleen                     | $1.37 \times 10^{0}$     |
| Thymus                     | $6.95 \times 10^{-2}$    |
| Thymus                     | $7.19 \times 10^{-2}$    |
| Urinary Bladder Wall       | $7.23 \times 10^{-2}$    |
| Uterus                     | $7.43 \times 10^{-2}$    |
| Tumor (0.5 g) $^c$         | $3.82 \times 10^{-2}$    |
| Total Body                 | $1.31 \times 10^{-1}$    |
| Effective Dose             | $1.71 \times 10^{-1}$    |

$^a$ The radiation dosimetry was converted from the biodistribution of $^{177}$Lu-pAuNS in 0.025 kg mice to 73 kg male adults. $^b$ LLI: Lower Large Intestine; ULI: Upper Large Intestine. $^c$ The tumor absorbed dose was obtained by the sphere model. The unit is mGy/MBq because no organ weighting factor is available for the sphere model.
4. Discussion

In this study, we applied brachytherapy for the treatment of orthotopic HNSCC tumors using intratumoral injection of $^{177}$Lu-DTPA-pAuNS. This local chemoradiotherapy method can deliver a relatively precise quantity of high-dose-rate radiopharmaceutical to specific tumor positions so that the risk of side effects is minimized [30–32]. Brachytherapy has also been applied in different types of HNSCC, including nasopharyngeal cancer, and oral cancer [33,34]. Although most nanocarriers for in vivo drug delivery are injected through vessels, nanoparticles are notorious for long-term accumulation in the liver and spleen by the reticuloendothelial system [35]. Therefore, the safety of radionuclide-conjugated nanoparticles is inevitably questioned because of radiation-induced damage to vital organs. The brachytherapy approach using intratumoral injection is a highly recommended route to be considered for preclinical and clinical treatment of HNSCC in a tumor model. The biodistribution analysis data have shown only a little dissemination of $^{177}$Lu-DTPA-pAuNS to normal organs away from the orthotopic tumor by intratumoral injection compared to that by intravenous injection. Because the half-life of $^{177}$Lu is more than six days, a longer accumulation of $^{177}$Lu-DTPA-pAuNS in normal organs may possibly endow unexpected side effects [36]. Therefore, intratumoral injection of the nanoparticle-embedded radiopharmaceutical is an interesting approach for HNSCC treatment.

The 5-years survival rate of HNSCC is around 50% after adjuvant chemoradiotherapy [37]. Local invasiveness of HNSCC is associated with EMT and is also a factor that affects the therapeutic efficacy. We have previously shown that intravenous injection of $^{188}$Re-liposome radiopharmaceutical could induce let-7i microRNA in orthotopic HNSCC tumors [29]. Furthermore, RNA-seq analysis revealed that a panel of microRNAs with tumor-suppressive and oncogenic characteristics were up-regulated and down-regulated, respectively, in $^{188}$Re-liposome treated HNSCC tumors [38]. The expression of EMT molecules was also influenced by $^{188}$Re-liposome to account for the potential therapeutic efficacy of this radiopharmaceutical [7]. Current data has shown that the use of intratumoral injection led to significant retention of $^{177}$Lu-DTPA-pAuNS in the HNSCC tumor model. However, little is known about the tumor-suppressive mechanisms of $^{177}$Lu-DTPA-pAuNS. For precise or personal therapy, it is critical to investigate the therapeutic mechanisms of this novel radiopharmaceutical.

For intravenous injection of $^{177}$Lu-DTPA-pAuNS, the radioactivity detected in the SAS xenograft tumor was approximately $1.17 \pm 0.13\%\text{ID/g}$ and $0.59 \pm 0.36\%\text{ID/g}$ after 24 h and 48 h, respectively (Figure S1). Most of the radioactivity was detected in the liver and spleen. This result is similar to that observed in our previous study, wherein, we used SKOV-3 xenograft tumors injected with $^{111}$In-DTPA-pAuNS intravenously [26]. Regarding the significant anti-tumoral effect of intravenously delivered AuNS-mediated PTT [26], we expected that the tumor-suppressing effect of intratumorally injected AuNS plus laser exposure should be more apparent because of the higher amount of AuNS accumulated in tumor lesions. Unexpectedly, there were no mice with complete tumor regression based on caliper-measured tumor volumes (Figure S2A,B). However, the H&E staining confirmed that the residual masses were nonviable scar tissues rather than live tumor cells (Figure S2C). These results suggest the potential of combining $^{177}$Lu-DTPA-pAuNS brachytherapy and PTT against HNSCC.

5. Conclusions

Current data demonstrate the long retention and therapeutic efficacy of the intratumoral injection of $^{177}$Lu-DTPA-pAuNS into an orthotopic HNSCC tumor model with little radiation exposure to normal organs. Because AuNS has been applied in PTT for superficial tumor lesions, conjugation of $^{177}$Lu with AuNS may provide a novel adjuvant brachytherapy approach for cancer treatment.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/pharmaceutics13111903/s1, Table S1: Biodistribution of intravenous injection of 177Lu-DTPA-AuNS in HNSCC orthotropic tumor model; Figure S1: Intravenously injection of 177Lu-DTPA-pAuNS in HNSCC orthotropic tumor model. (A) μSPECT/CT imaging of 177Lu-DTPA-pAuNS. (B) The activity of the tumor area at different time points; Figure S2: Photothermal therapy treatment of pAuNS. (A) Thermal imaging of pAuNS-mediated PTT. (B) Comparison of tumor growth in pAuNS and pAuNS-mediated PTT. (C) H&E staining of HNSCC tumor. The nuclei and the cytoplasm were stained with haematoxylin (blue) and eosin (red).

Author Contributions: Conceptualization, C.-Y.W. and Y.-J.L.; methodology, M.-Y.L. and H.-H.H.; software, H.-H.H.; validation, J.-C.C.; C.-C.C. and W.-S.H.; formal analysis, T.-W.C.; investigation, M.-Y.L., H.-H.H. and N.-C.S.; resources, S.-Y.H. and T.-W.C.; data curation, M.-Y.L. and H.-H.H.; writing—original draft preparation, Y.-J.L.; writing—review and editing, C.-Y.W.; visualization, Y.-J.L. and H.-H.H.; supervision, J.-C.C. and S.-Y.H.; project administration, Y.-J.L.; funding acquisition, Y.-J.L. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by an intramural grant of National Yang Ming University and National Chiao Tung University (109AC-DYC604), and a grant from Ministry of Science and Technology of Taiwan (110-2623-E-010-004-NU and 109-2314-B-010-066).

Institutional Review Board Statement: All the experiment animals were approved by the Institutional Animal Care and Use Committee (IACUC No. 1081009).

Informed Consent Statement: Not applicable.

Data Availability Statement: Data generated or analyzed during the study are available from the corresponding author by request.

Acknowledgments: We thank the support from Cancer Progression Research Center, National Yang Ming Chiao Tung University. We thank the facility supported by the Molecular and Genetic Imaging Core/National Research Program for Genomic Medicine.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Pulte, D.; Brenner, H. Changes in survival in head and neck cancers in the late 20th and early 21st century: A period analysis. Oncologist 2010, 15, 994–1001. [CrossRef] [PubMed]
2. Chang, J.H.; Wu, C.C.; Yuan, K.S.; Wu, A.T.H.; Wu, S.Y. Locoregionally recurrent head and neck squamous cell carcinoma: Incidence, survival, prognostic factors, and treatment outcomes. Oncotarget 2017, 8, 55600–55612. [CrossRef] [PubMed]
3. Garavello, W.; Ciardo, A.; Sprefacio, R.; Gaini, R.M. Risk factors for distant metastases in head and neck squamous cell carcinoma. Arch. Otolaryngol. Head Neck Surg. 2006, 132, 762–776. [CrossRef] [PubMed]
4. Yang, W.H.; Lan, H.Y.; Huang, C.H.; Tai, S.K.; Tseng, C.H.; Kao, S.Y.; Wu, K.J.; Hung, M.C.; Yang, M.H. RAC1 activation mediates Twist1-induced cancer cell migration. Nat. Cell Biol. 2012, 14, 366–374. [CrossRef]
5. Jimenez, L.; Jayakar, S.K.; Ow, T.J.; Segall, J.E. Mechanisms of Invasion in Head and Neck Cancer. Arch. Pathol. Lab. Med. 2015, 139, 1334–1348. [CrossRef]
6. van der Heijden, M.; Essers, P.B.M.; Verhagen, C.V.M.; Willems, S.M.; Sanders, J.; de Roest, R.H.; Vossen, D.M.; Leemans, C.R.; Verheij, M.; Brakenhoff, R.H.; et al. Epithelial-to-mesenchymal transition is a prognostic marker for patient outcome in advanced stage HNSCC patients treated with chemoradiotherapy. Radiother. Oncol. 2020, 147, 186–194. [CrossRef]
7. Chang, C.Y.; Chen, C.C.; Lin, L.T.; Chang, C.H.; Chen, L.C.; Wang, H.E.; Lee, T.W.; Lee, Y.J. PEGylated liposome-encapsulated rhenium-188 radiopharmaceutical inhibits proliferation and epithelial-mesenchymal transition of human head and neck cancer cells in vivo with repeated therapy. Cell Death Dis. 2018, 4, 100. [CrossRef]
8. Ma, Y.; Zhao, G.; Qi, J.; Sun, P.; Liu, C.; Qu, P.; Chan, K.K.L. Neoadjuvant brachytherapy and chemotherapy followed by radical surgery for stage IB2 and IIA cervical cancer: A retrospective comparison with chemoradiation. Mol. Clin. Oncol. 2018, 8, 617–622. [CrossRef]
9. Sgouros, G.; Bodei, L.; McDevitt, M.R.; Nedrow, J.R. Radiopharmaceutical therapy in cancer: Clinical advances and challenges. Nat. Rev. Drug Discov. 2020, 19, 589–608. [CrossRef]
10. Ritter, M.; Teudt, I.U.; Meyer, J.E.; Schroder, U.; Kovacs, G.; Wollenberg, B. Second-line treatment of recurrent HNSCC: Tumor debulking in combination with high-dose-rate brachytherapy and a simultaneous cetuximab-paclitaxel protocol. Radiat Oncol. 2016, 11, 6. [CrossRef]
11. Bhavat, R.; Pareek, V.; Chandra, M.; Nelllore, L.; George, K.; Borade, D.; Kalariya, K.; Moosa, Z.; Srivastava, A.; Reddy, N.; et al. High-dose-rate interstitial brachytherapy in recurrent head and neck cancer: An effective salvage option. J. Contemp. Brachyther. 2018, 10, 425–430. [CrossRef]
12. Herrero Alvarez, N.; Bauer, D.; Hernandez-Gil, J.; Lewis, J.S. Recent Advances in Radiometals for Combined Imaging and Therapy in Cancer. ChemMedChem 2021, 16, 2999–2941. [CrossRef]

13. Kumar, A.; Ballal, S.; Yadav, M.P.; ArunRaj, S.T.; Haresh, K.P.; Gupta, S.; Damle, N.A.; Garg, A.; Tripathi, M.; Bal, C. 177Lu/68Ga-PSMA Theranostics in Recurrent Glioblastoma Multiforme: Proof of Concept. Clin. Nucl. Med. 2020, 45, e512–e513. [CrossRef]

14. Das, T.; Banerjee, S. Theranostic Applications of Lutetium-177 in Radionuclide Therapy. Curr. Radiopharm. 2016, 9, 94–101. [CrossRef]

15. Dash, A.; Pillai, M.R.; Knapp, F.F., Jr. Production of (177)Lu for Targeted Radionuclide Therapy: Available Options. Nucl. Med. Mol. Imaging 2015, 49, 85–107. [CrossRef]

16. Muller, C.; van der Meulen, N.P.; Benesova, M.; Schibli, R. Therapeutic Radiometals Beyond (177)Lu and (90)Y: Production and Application of Promising alpha-Particle, beta(-)-Particle, and Auger Electron Emitters. J. Nucl. Med. 2017, 58, 915–965. [CrossRef]

17. Khoury, C.G.; Vo-Dinh, T. Gold Nanostars For Surface-Enhanced Raman Scattering: Synthesis, Characterization and Optimization. J. Phys. Chem. C Nanomater. 2008, 108, 18849–18859. [CrossRef]

18. Tian, F.; Conde, J.; Bao, C.; Chen, Y.; Curtin, J.; Cui, D. Gold nanostars for efficient in vitro and in vivo real-time SERS detection and drug delivery via plasmonic-tunable Raman/FTIR imaging. Biomaterials 2016, 106, 87–97. [CrossRef]

19. Chen, H.; Kou, X.; Yang, Z.; Ni, W.; Wang, J. Shape- and size-dependent refractive index sensitivity of gold nanoparticles. Langmuir 2008, 24, 5233–5237. [CrossRef]

20. Hao, F.; Nehl, C.L.; Hafner, J.H.; Nordlander, P. Plasmon resonances of a gold nanostar. Nano Lett. 2007, 7, 729–732. [CrossRef]

21. Mousavi, S.M.; Zarei, M.; Hashemi, S.A.; Ramakrishna, S.; Chiang, W.H.; Lai, C.W.; Gholami, A. Gold nanostars-diagnosis, bioimaging and biomedical applications. Drug Metab. Rev. 2020, 52, 299–318. [CrossRef]

22. Liu, Y.; Yuan, H.; Fales, A.M.; Register, J.K.; Vo-Dinh, T. Multifunctional gold nanostars for molecular imaging and cancer therapy. Front. Chem 2015, 3, 51. [CrossRef]

23. Kim, C.; Song, H.M.; Cai, X.; Yao, J.; Wei, A.; Wang, L.V. In vivo photoacoustic mapping of lymphatic vessels with plasmon-resonant nanostars. J. Mater. Chem. 2011, 21, 2841–2848. [CrossRef]

24. Li, C.; Zhang, Y.; Wan, Y.; Wang, J.; Lin, J.; Li, Z.; Huang, P. STING-activating drug delivery systems: Design strategies and biomedical applications. Chin. Chem. Lett. 2021, 32, 1615–1625. [CrossRef]

25. Gherman, A.M.M.; Boca, S.; Vulpoi, A.; Cristea, M.V.; Farcau, C.; Tosa, V. Plasmonic photothermal heating of gold nanostars in a real-size container: Multiscale modelling and experimental study. Nanotechnology 2020, 31, 125701. [CrossRef]

26. Chen, C.C.; Chang, D.Y.; Li, J.J.; Chan, H.W.; Chang, C.H.; Liu, R.S.; Chang, C.A.; Chen, C.L.; Wang, H.E. Investigation of biodistribution and tissue penetration of PEGylated gold nanostars and their application for photothermal cancer treatment in tumor-bearing mice. J. Mater. Chem B 2020, 8, 65–77. [CrossRef]

27. Fernandez-Montoto, A.; Gorbe, M.; Llopis-Lorente, A.; Terres, J.M.; Montes, R.; Cao-Milan, R.; Diaz de Genu, B.; Alfonso, M.; Orzaez, M.; Marcos, M.D.; et al. A NIR light-triggered drug delivery system using core-shell gold nanostars-mesoporous silica nanoparticles based on multiphoton absorption photo-dissociation of 2-nitrobenzyl PEG. Chem. Commun. 2019, 55, 9039–9042. [CrossRef]

28. Yook, S.; Cai, Z.; Lu, Y.; Winnik, M.A.; Pignol, J.P.; Reilly, R.M. Intratumorally Injected 177Lu-Labeled Gold Nanoparticles: Gold Nanoseed Brachytherapy with Application for Neoadjuvant Treatment of Locally Advanced Breast Cancer. J. Nucl. Med. 2016, 57, 936–942. [CrossRef]

29. Smith, G.L.; Jiang, J.; Buchholz, T.A.; Xu, Y.; Hoffman, K.E.; Giordano, S.H.; Hunt, K.K.; Smith, B.D. Benefit of adjuvant brachytherapy versus external beam radiation for early breast cancer: Impact of patient stratification on breast preservation. Int. J. Radiat. Oncol. Biol. Phys. 2014, 88, 274–284. [CrossRef]

30. Chen, M.; Huang, X.; Lai, J.; Ma, L.; Chen, T. Substituent-regulated highly X-ray sensitive Os(VI) nitrido complex for low-toxicity radiotherapy. Chin. Chem. Lett. 2021, 32, 158–161. [CrossRef]

31. Ma, H.; Wu, Y.; Zhang, W.; Zhang, H.; Miao, Z.; Zhuang, C. Radiosensitization of human pancreatic cancer by piperlongumine analogues. Chin. Chem. Lett. 2021, 32, 1197–1201. [CrossRef]

32. Lee, N.; Hoffmann, R.; Phillips, T.L.; Xia, P.; Quivey, J.M.; Weinberg, V.; Hsu, I.C. Managing nasopharyngeal carcinoma with intracavitary brachytherapy: One institution’s 45-year experience. Brachytherapy 2002, 1, 74–82. [CrossRef]

33. Yamazaki, H.; Yoshida, K.; Yoshioha, Y.; Shimizutani, K.; Furukawa, S.; Koizumi, M.; Ogawa, K. High dose rate brachytherapy for oral cancer. J. Radiat Res. 2013, 54, 1–17. [CrossRef] [PubMed]

34. Almeida, J.P.; Chen, A.L.; Foster, A.; Drezek, R. In vivo biodistribution of nanoparticles. Nanomedicine 2011, 6, 815–835. [CrossRef]

35. Long, W.; Wang, J.; Xu, F.; Wu, H.; Mu, X.; Wang, J.; Sun, Y.; Zhang, X.-D. Catalytic PtPd bimetal nanocrystals with high-index facets for radiation injury repair. Chin. Chem. Lett. 2020, 31, 269–274. [CrossRef]

36. Begg, A.C. Predicting recurrence after radiotherapy in head and neck cancer. Semin. Radiat. Oncol. 2012, 22, 108–118. [CrossRef]

37. Lin, L.T.; Chang, C.Y.; Chang, C.H.; Wang, H.E.; Chiou, S.H.; Liu, R.S.; Lee, T.W.; Lee, Y.J. Involvement of let-7 microRNA for the therapeutic effects of Rhenium-188-embedded liposomal nanoparticles on orthotopic human head and neck cancer model. Oncotarget 2016, 7, 65782–65796. [CrossRef]

38. Lin, B.Z.; Wan, S.Y.; Lin, M.Y.; Chang, C.H.; Chen, T.W.; Yang, M.H.; Lee, Y.J. Involvement of Differentially Expressed microRNAs in the PEGylated Liposome Encapsulated (188)Rhenium-Mediated Suppression of Orthotopic Hypopharyngeal Tumor. Molecules 2020, 25, 3609. [CrossRef]